Chemokine-receptor-guided B-cell immunity in cardiovascular disease.
Anais Yerly, Emiel P C van der Vorst, Marc Schindewolf...
https://pubmed.ncbi.nlm.nih.gov/40986007/Actively Recruiting
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-08-12
372
Participants Needed
1
Research Sites
26 weeks
Total Duration
Researchers are evaluating how a single injection of rituximab affects heart function after an acute anterior ST-elevation myocardial infarction STEMI. This European phase IIb trial compares a 1000 mg dose of rituximab to a placebo, focusing on left ventricular systolic function measured by cardiac magnetic resonance imaging CMR at 6 months. The study aims to understand the impact of B cell depletion on heart remodeling and dysfunction following a heart attack. Participants will receive either a single infusion of 1000 mg rituximab or a placebo within 3 hours after primary percutaneous coronary intervention PPCI. The study involves random assignment to one of these two groups. Blood samples for biomarkers related to immune response and inflammation will be collected at admission, discharge, and 6 months. Continuous cardiac telemetry and ECG measurements will monitor patients during and after infusion. CMR scans will assess heart function and damage at 5 days and 6 months post-treatment. Throughout the study, participants will undergo blood tests for kidney function, hematologic parameters, and NT-pro-BNP at specified timepoints. Follow-up contacts by phone or hospital visits will occur at 30 days, 3 months, and 12 months after randomization. The primary outcome is left ventricular ejection fraction at 6 months, with additional measures including infarct size, edema, microvascular obstruction, and treatment-related adverse events. Participant involvement lasts through the 12-month follow-up period.
CONDITIONS
Rituximab in Patients With ST-elevation Myocardial Infarction
G
Gabriel STEG
Z
Ziad MALLAT
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Single administration shortly after PCI
Participants receive a single infusion of either 1000 mg rituximab or placebo within 3 hours after primary PCI. They are monitored closely with continuous cardiac telemetry and ECG during and after infusion.
1 hospital visit for infusion and monitoring
Duration - 6 months
Participants undergo cardiac magnetic resonance imaging (CMR) at 5 days and 6 months to evaluate heart function and damage. Blood tests for biomarkers and kidney function are performed at admission, day 5, discharge, and 6 months.
Multiple visits for imaging and blood tests
Duration - Up to 12 months
Researchers contact participants by phone or hospital visits at 30 days, 3 months, and 12 months after randomization to monitor health and any adverse events.
3 follow-up contacts
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Anais Yerly, Emiel P C van der Vorst, Marc Schindewolf...
https://pubmed.ncbi.nlm.nih.gov/40986007/Assistance Publique - Hôpitaux de Paris
Lead Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborating Sponsor